cyrilzakka/clinical-trials huggingface dataset:
Genetic Studies in Alzheimer's Disease

Alzheimer's disease is a condition marked by the deterioration of mental function. The disease usually begins in late middle life and results in death in 5 to 10 years. Patients with Alzheimer's disease typically suffer from memory loss, confusion, and disorientation. The condition has become a major medical and social problem in the United States because of the increasing number of people living beyond the age of 65. The actual cause of Alzheimer's disease is unknown.

Researchers believe that Alzheimer's disease, or at least a portion of cases, may be an inherited condition. As a result, many new techniques have been developed to study the genetic causes of Alzheimer's disease and other neurological disorders. Many of these genetic techniques require blood samples and a family pedigree. A pedigree is a chart, similar to a family tree, that shows a patient's family history.

The purpose of this study is to collect family and psychosocial information, blood, and biopsy samples from patients with neurological diseases, their families, and normal volunteers. This information gathered will be used to learn more about diseases that affect the brain.

This is a screening and follow-up Protocol. Recent technological advances have facilitated the development of new approaches for investigating the underlying genetic basis of neurological disorders, but genetic questions remain open and on going. Application of many genetic techniques require a family pedigree and blood sample. Peripheral blood lymphoblasts which are banked also serve as a renewable source for harvesting DNA which can be used for developing genetic markers in the future. This study will allow collection of family and psychosocial information and blood specimens from patients with neurological diseases, their families, and normal control subjects.

Eligibility Criteria:
INCLUSION/EXCLUSION CRITERIA

Need to know extensive family history information.
Different Modes of Temperature Measurement in the Emergency Department

Introduction: Temperature measurement is a crucial and integral element in the assessment of the emergency department patients. The basis of triage and treatment is often directly influenced by temperature measurement. The finding of hyper/hypothermia may differentiate between a simple urinary tract infection and pyelonephritis, or in more extreme cases may discern "weakness" in the elderly from sepsis. This brief encounter of temperature measurement may be paramount to the medical treatment of the emergency department patient. The investigators will explore the different modes of temperature measurements in emergency department patients.

Temperature measurement is a crucial and integral element in the assessment of the emergency department patients. The basis of triage and treatment is often directly influenced by temperature measurement. The finding of hyper/hypothermia may differentiate between a simple urinary tract infection and pyelonephritis, or in more extreme cases may discern "weakness" in the elderly from sepsis. This brief encounter of temperature measurement may be paramount to the medical treatment of the emergency department patient.We will explore the different modes of temperature measurements in emergency department patients. We will check which temperature measurement is beneficial.

Eligibility Criteria:
Inclusion Criteria:

* patients who arrive to the emergency department

Exclusion Criteria:

* patients who refuse
PNEUMACRIT Device for Neonatal Cardio Respiratory Monitoring

The usability of a new PNEUMACRIT system is studied in clinical environment in this feasibility study.

Electrical impedance tomography is a noninvasive monitoring tool for neonatal lung aeration and breathing. This feasibility study will assess the usability of a new PNEUMACRIT electrode belt in clinical environment.

Eligibility Criteria:
Inclusion Criteria:

* Inpatient at Oulu University Hospital PICU or NICU
* Gestational age at birth over 32 weeks
* Weight 2000-5000g
* Postnatal age \> 12 hours
* Written informed consent from the parents of legal representative
* Non-invasive monitoring of oxygen saturation and ECG

Exclusion Criteria:

* Postmenstrual age \< 32 weeks
* Weight at time of the study \< 2000g or \> 5000g
* Chest skin lesion preventing safe use of the electrode belt
* Recent chest surgery within the past 7 days (e.g. thoracotomy)
Prophylactic Antibiotic in Subtalar Fusion Surgery

Assessment of surgical site infection when using postoperative antibiotic prophylaxis in subtalar fusion surgery 24hours versus 5 days

Infection in orthopedic surgery is one of the most dreaded complications. Antibiotic prophylaxis should be utilized routinely in foot and ankle surgeries involving bone, utilizing hardware and prosthetic joints.

It is appropriate for the antibiotics to be administered within 60 minutes prior to surgery, discontinued within 24 hours after surgery, given prior to tourniquet inflation, and utilized routinely in prolonged foot and ankle surgery cases.

Narrow spectrum antibiotics covering Staphylococcus aureus should be utilized for prophylaxis in patients without a history of resistant infection. According to American Society of Health System Pharmacists (ASHP) cefazolin was the most used antibiotic in preoperative prophylaxis, combination of cefazolin with gentamicin was the second common regimen while 3rd generation cephalosporin were 3rd widely used antibiotics.

The controversy persists in administration of antibiotics varying from a single dose to 3 doses to 5 days or 14 days. In subtropical country, with a hot and humid climate is a conducive environment for both Gram-positive and Gram-negative bacterial colonization of skin. Therefore, we need studies tailored to our environment in Egypt Prevention of SSIs is critical for the health of patients, Economic efficiency, Antibiotic resistance considerations In conclusion, in many ways, the topic of prophylactic antibiotics in elective foot and ankle surgery is an unusual one, in that a relative divide exists between empirical science and common practice.

Eligibility Criteria:
Inclusion Criteria:

1. posttraumatic subtallar osteoarthritis
2. adult age 18 up to 60
3. good skin condition healthy

Exclusion Criteria:

1. comorbidities such as Diabetes Mellitus, Autoimmune diseases
2. previous foot surgery
3. wounds near surgical incision
4. skin infection
Physical Activity Assessment of Patients With Diabetic Foot Wounds

The study evaluates the compliance of patients who suffer from a diabetic foot wound to follow a physical activity program, adapted to their medical condition.

This study will aslo evaluate the security of this program, and how it could improve or not the quality of life, the diabet's metabolical balance, and the wounds's cicatrization speed.

The study is a prospective monocentric study, leaded in the Lille CHRU. this study is a physical activity program feasibility assessment for patients with diabetic foot wounds. The muscular mass stabilization and the physical activity is almost never used to heal diabetic feet wounds. With this study, we evaluate the compliance of patients to follow a physical activity program, which could lead to a further study, with more patients and multicentric, and it could measure the impact of this program on metabolical balance, wound size and quality of life.

The study will last 6 months, the inclusion will last 3 months, and each patient will have a 3 months follow-up time. The patient have several medical appointments in the diabetic foot unit, where the compliance will be evaluated, wound size and security will also be evaluated.

The activity program is a suite of exercises, 4 times in a week, it lasts 30 minutes?

The first day, follow-up book is given to the patient. During the follow-up, the patient will still have his usual medical appointments, which will occur at the 30th, 60th and 90th days.

Phone-call appointments will also be possible at the 15th and 45th days.

Eligibility Criteria:
Inclusion Criteria:

* Men and women
* Every patient over 18 years old
* Diabet whatever the type, with foot wound, whatever the size, or duration.

Exclusion Criteria:

* Medical condition : sub-gonal amputation, which makes physical activity impossible. Wound localization which would lead to a wound degradation, like the heel, the plantar face of toes.
* Administrative cause : impossibility to provide written informed consent, impossibility to be followed up during the needed duration, no medical insurance, rejection to sign the consent paper.
Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy

Radiation therapy is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma. Our previous preclinical investigation revealed that radiotherapy can initiate immunogenic cell death and facilitate the cross-presentation of tumor antigens by antigen-presenting cells, thereby augmenting systemic anti-tumor T cell responses in murine tumor models. However, this immune response subsequent to irradiation has not been comprehensively evaluated in clinical trials involving hepatocellular carcinoma patients. Given that radiotherapy represents a standard therapeutic approach for unresectable hepatocellular carcinoma, our ongoing phase II non-randomized trial aims to prospectively assess immunological responses and dose-volumetric parameters, while identifying predictors of clinical outcomes in patients undergoing definitive radiotherapy for hepatocellular carcinoma.


Eligibility Criteria:
Inclusion Criteria:

1. Participants must have diagnosis of HCC. Participants may have multiple lesions. Diagnosis should be confirmed by at least 1 criteria listed below:

   * Histologically or cytologically proven diagnosis of HCC.
   * Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
2. Age ≥18 years at the time of signing informed consent document.
3. ECOG performance status 0-2.
4. Child-Pugh score 5-9 liver function within 28 days of study registration.
5. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.
6. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.
7. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

1. Presence of distant metastases that cannot be encompassed by radiotherapy
2. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
3. Inability to treat all sites of disease by radiotherapy
4. Known HIV infection.
Smartphone Apps for Pediatric Resuscitation

Medication errors are common in children. Characteristics of errors during critical situations in the Emergency Department are ill-defined and might be more frequent than previously thought. However, optimal strategies to eliminate the risk of prescribing errors remain unknown.

Many smartphone apps have been suggested over the last years with some of them designed to calculate medication dosage for children. The impact of these apps to decrease dosage error has never been evaluated in resuscitation setting.

The aim of the study is to evaluate whether the use of a smartphone application designed to calculate medication doses decreases prescribing errors among residents during pediatric simulated resuscitations.

This will be a crossover-randomized trial using high fidelity simulation among 40 residents rotating in the pediatric emergency department.


Eligibility Criteria:
Inclusion Criteria:

* Residents (PGY1 to PGY4)
* Completing a rotation in pediatric emergency

Exclusion Criteria:

* Residents who previously participated in this study
Formative Development of a Multigenerational eHealth Intervention for Grandparents and Grandchildren

This study develops a multigenerational electronic Health (eHealth) (web and mobile phone-based) program to improve physical activity levels and to better understand the relationship between grandparents and their grandchildren. The importance of social and familial support for older adults and the need to address increasing declines in physical activity for both children and older adults. Health promotion interventions that capitalize on the existing relationship between grandparents and grandchildren may simultaneously improve health-related outcomes for older adults and children.


Eligibility Criteria:
Inclusion Criteria:

* Female or male grandparent with a grandchild
* Grandparent is at least 45 years old
* Grandparent has a grandchild between the ages of 6-12 years old
* Grandparent is English or Spanish speaking

Exclusion Criteria:

* Grandparent has a chronic medical condition that interferes with physical activity (e.g., wheelchair bound, severe heart disease, uncontrolled hypertension, brittle diabetes mellitus, chronic arthritis)
* Grandparent has a diagnosis of dementia or significant cognitive impairment based on the telephone interview for cognitive status (TICS)
Vitamin D and Omega-3 Inhibit Metabolic Syndrome

The study will test the hypothesis that supplementing the diet of subjects with Metabolic Syndrome with 2000 IU vitamin D and 1.8 g omega-3 fatty acids (EPA + DHA) per day, will facilitate weight loss, improve body composition and reduce metabolic and biochemical risk factors associated with type II diabetes and cardiovascular disease. Adult men and women who meet the International Diabetes Federation criteria for Metabolic Syndrome will be enrolled and embark on a 16 week diet and exercise intervention using a low glycemic index diet with or without the supplementary vitamin D and omega-3. Subjects will be counseled weekly and blood collected at weeks 0 and 16.


Eligibility Criteria:
Inclusion Criteria:

* must have Metabolic Syndrome as defined by International Diabetes Federation
* must be able to swallow tablets and capsules
* must be 18 years of age or older
* must be physically capable of moderate intensity exercise

Exclusion Criteria:

* pregnant or lactating
* vegetarian
Prevalence of Long-term Dental Effects of Chemotherapy in Childhood Cancer Survivors Diagnosed With Cancer Before the Age of 10

To date, there are no methods for assessing the risk of oral developmental defects that could predict long-term adverse effects in childhood cancer survivors. Having such a method at our disposal would enable us to better assess the risk to develop those defects and will help us provide new prevention and treatment strategies to ensure a healthy oral development.

The aims of this study are :

* Assess the caries risk in childhood cancer survivors compared with a control group.
* Assess the dental development defects risk in childhood cancer survivors compared with a control group.

This will be an international study comparing the Childhood Cancer Survivors (CCS) and a control group.

A questionnaire will be provided to the patients to gather information. A standard of care dental examination will then take place in a dental office in the Cliniques Universitaires Saint-Luc. We also collect medical data to complete the files.

Eligibility Criteria:
Inclusion Criteria:

* age below 10 at cancer diagnosis (for the CCS group).
* Chemotherapy must have been used to treat the patient (For the CCS group).
* The patient is 12 years old or older at the time of the follow-up appointment of the present study

Exclusion Criteria:

* A patient who was diagnosed and treated after 10 years old.
* Patient below 12 years old at time of study recruitment
* Patients with syndrome or diseases that involve teeth impairment\*
* Pregnant patient
* Refusal or inaptitude to undergo dental and radiographic examination
Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.

The purpose of the study is to determine whether low-dose aspirin and low molecular weight heparin improve the implantation and pregnancy rates in patients with repeated implantation failures in IVF cycle.

The investigators hypothesize that cotreatment of low dose aspirin \& low molecular weight heparin may improve implantation \& clinical pregnancy rates.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 19 to 35 years;
* Basal follicle-stimulating hormone (FSH) levels of ≤8 IU/l
* Body mass index (BMI) between 19 kg/m2 and 25 kg/m2
* Presence of both ovaries; ≥2 previous IVF failures
* Good quality embryos for transfer
* Endometrial thickness between 10 mm and 14 mm

Exclusion Criteria:

* Polycystic ovary syndrome
* Endometriosis
Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function

The study is designed to demonstrate the safety, feasibility and potential efficacy of using the AccuCinch® System to reduce functional mitral regurgitation.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* Subjects with clinically significant mitral regurgitation (MR 2+ and above)
* Ejection Fraction ≥ 25%
* Stable cardiac medical regimen for heart failure for at least 1 month
* Stable NYHA Classification for at least 1 month
* Subject is eligible for cardiac surgery
* The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent

Exclusion Criteria:

* Myocardial infarction within 90 days of the intended treatment with the device
* Prior surgical, transcatheter, or percutaneous mitral valve intervention
* Any intervention for coronary artery disease (CAD) within the last 30 days prior to treatment, or unrevascularized multivessel coronary disease
* Hemodynamic instability or the need for emergent surgery
* Non-ambulatory NYHA Class IV symptoms of heart failure or subjects requiring IV inotropic support
* Subjects in whom sufficient quality of echocardiography (TTE and TEE) cannot be obtained
* Echocardiography evidence of primary mitral valve disease causing MR or MS,
* Evidence of mitral valve stenosis with an estimated valve area less than 3.0 cm2
* Mitral valve prosthesis or pathology that would prevent adequate function of the GDS Accucinch System
* Estimated GFR of \<30ml/min/1.73m2
* Greater than mild mitral annular calcification observed by fluoroscopy
* Presence of aortic valve prosthesis
* Moderate to severe aortic valve stenosis or calcification observed by echocardiography or fluoroscopy
* Severe aortic arch calcification or mobile aortic atheroma observed by echocardiography or fluoroscopy
* Active bacterial endocarditis
* History of bleeding diathesis or coagulopathy
* History of stroke within the prior 6 months
* Subjects in whom anticoagulation is contraindicated
* Any clinical evidence that the investigator feels would place the subject at increased risk with the placement of the device.
* Concurrent medical condition with a life expectancy of less than 12 months
* Currently participating in an investigational study
* Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. severe chronic obstructive pulmonary disease, hepatic failure, immunological abnormalities, and hematological abnormalities)
* Subjects with indication for concomitant surgery such as coronary artery bypass graft (CABG), aortic valve reconstruction or replacement, tricuspid repair or replacement, left ventricular remodeling surgery and congenital repair
* Any cardiac resynchronization therapy within the last 3 months prior to treatment
* Subjects on high dose steroids or immunosuppressant therapy
* Female subjects who are pregnant, of child bearing potential or lactating
* Subjects who are unable or unwilling to comply with the follow-up schedule and requirements
Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)

Approximately 1/3 of persons living with HIV infection are co-infected with tuberculosis (TB). Rifabutin, used in the treatment of TB, is an inducer of drug metabolism thus may decrease concentrations of lersivirine if co-administered. Lersivirine is a modest inducer of drug metabolism, thus lersivirine may decrease concentrations of rifabutin as well.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
* History of regular alcohol consumption exceeding 7 drinks/week for women and 14 drinks/week for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor).
* Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
* Hypersensitivity/allergic reactions to any component of the study drugs.
Combinations of Pharmacologic Smoking Cessation Treatments

The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.


Eligibility Criteria:
Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health
A Relative Bioavailability Study of LY3209590 in Healthy Participants

The study will be conducted in two parts (part A and part B). The main purpose of this study is to compare the amount of LY3209590 that gets into the blood stream and how long it takes the body to get rid of it, when self-administered at different body sites, abdominal wall, upper arm and thigh (part A), when administered by two different routes of injection, subcutaneously or intravenously (part B) in healthy participants.

The study may last up to 65 (part A) and 184 (part B) days, respectively.


Eligibility Criteria:
Inclusion Criteria:

* Male or female participants who are overtly healthy as determined by medical evaluation
* Participants with body mass index (BMI) within the range 18.5 to 35.0 kilograms per meter squared (kg/m²)
* Male or female participants must agree to use contraception

Exclusion Criteria:

* Have a history of multiple or severe allergic reactions or a history of severe anaphylactic reaction
* Have known allergies to LY3209590, related compounds, or any components of the formulation
* Have an abnormality in the 12-lead electrocardiogram
* Intend to use prescription medication, including herbal medications and traditional medications
* Show evidence of human immunodeficiency virus infection or positive human immunodeficiency virus antibodies, hepatitis C or positive hepatitis C antibody, or hepatitis B or positive hepatitis B surface antigen
* Are lactating or pregnant